Tumor-to-background ratios of the maximum standardized uptake value could not indicate the prognosis of advanced high-grade serous ovarian cancer patients

被引:3
|
作者
Liu, Shuai [1 ,3 ,4 ,5 ]
Ju, Xingzhu [2 ,5 ]
Feng, Zheng [2 ,5 ]
Wen, Hao [2 ,5 ]
Xu, Junyan [1 ,3 ,4 ,5 ]
Chen, Xiaojun [2 ,5 ]
Wu, Xiaohua [2 ,5 ]
机构
[1] Fudan Univ, Shanghai Canc Ctr, Dept Nucl Med, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Dept Gynecol Oncol, 270 Dongan Rd, Shanghai 200032, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Ctr Biomed Imaging, Shanghai, Peoples R China
[4] Fudan Univ, Shanghai Canc Ctr, Shanghai Engn Res Ctr Mol Imaging Probes, Shanghai, Peoples R China
[5] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
关键词
F-18-FDG PET; CT; high-grade serous ovarian cancer; prognosis; tumor-to-background ratio; CONTRAST-ENHANCED CT; FDG-PET/CT; ASSOCIATION; PARAMETERS; SUVMAX; LIVER;
D O I
10.1097/MNM.0000000000000798
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
ObjectiveOur study aimed to explore the prognostic influence of tumor-to-background ratios (TBRs) of the maximum standardized uptake value (SUVmax) in advanced high-grade serous ovarian cancer (HGSC) patients.Patients and methodsWe retrospectively investigated 51 advanced HGSC patients who underwent PET/CT before primary surgery at our hospital between January 2010 and June 2015. None of these patients received neoadjuvant chemotherapy. SUVmax of ovarian tumor (SUVmax-P) and background (SUVmax-B) were measured using a PET/CT workstation. TBR was calculated by SUVmax-P/SUVmax-B. Backgrounds included the liver, mediastinum, and muscle, and TBRs were noted as TBR-L, TBR-Me, and TBR-Mu, respectively. The (2)-test was used to analyze the relationships between PET/CT parameters and several clinical features. Progression-free survival and overall survival were analyzed using the Kaplan-Meier method and log-rank tests in univariate analyses.ResultsThe median (range) follow-up duration was 27 (8-61) months. The median (range) PET/CT parameter values were as follows: SUVmax, 11.41 (3.24-24.14), TBR-L, 2.84 (2.08-11.93), TBL-Me, 2.09 (1.33-9.07), and TBR-Mu, 1.04 (0.56-14.02). The patients were categorized into low and high groups by the median values of these parameters above separately. A larger proportion of patients in the high TBR-Me group were chemoresistant compared with the low-value group (P=0.039). Neither the residual disease nor the ascites levels correlated with SUVmax or TBR values. There were no differences in progression-free survival and overall survival between the patients in the high and low TBR level groups.ConclusionTBRs of SUVmax were not prognostic indicators for advanced HGSC patients.
引用
收藏
页码:319 / 324
页数:6
相关论文
共 50 条
  • [31] Intratumoral and Peritumoral Radiomics for Predicting the Prognosis of High-grade Serous Ovarian Cancer Patients Receiving Platinum-Based Chemotherapy
    Huang, Xiaoyu
    Huang, Yong
    Liu, Kexin
    Zhang, Fenglin
    Zhu, Zhou
    Xu, Kai
    Li, Ping
    ACADEMIC RADIOLOGY, 2025, 32 (02) : 877 - 887
  • [32] Prognostic 18F-FDG Radiomic Features in Advanced High-Grade Serous Ovarian Cancer
    Morales, Daniela Travaglio
    Cabrerizo, Carlos Huerga
    Garcia, Itsaso Losantos
    Poggio, Monica Coronado
    Garcia, Jose Manuel Cordero
    Llobet, Elena Lopez
    Araujo, Domenico Monachello
    Monzon, Sebastian Rizkallal
    Gadea, Luis Dominguez
    DIAGNOSTICS, 2023, 13 (22)
  • [33] Composite score of PD-1+CD8+ tumor-infiltrating lymphocytes and CD57+CD8+ tumor ascites lymphocytes is associated with prognosis and tumor immune microenvironment of patients with advanced high-grade serous ovarian cancer
    He, Tianhui
    Zhang, Jie
    Zeng, Lin
    Yin, Zhongnan
    Yu, Bo
    Zhang, Xi
    Yang, Xiaoxue
    Shang, Chunliang
    Xue, Lixiang
    Guo, Hongyan
    CHINESE JOURNAL OF CANCER RESEARCH, 2025, 37 (01)
  • [34] Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients
    Zheng Feng
    Hao Wen
    Rui Bi
    Yachen Duan
    Wentao Yang
    Xiaohua Wu
    BMC Cancer, 16
  • [35] The Emerging Role of the Single-Cell and Spatial Tumor Microenvironment in High-Grade Serous Ovarian Cancer
    Launonen, Inga-Maria
    Vaharautio, Anna
    Farkkilae, Anniina
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2023, 13 (10):
  • [36] Skeletal muscle morphology in patients receiving primary versus interval cytoreductive surgery for advanced high-grade serous ovarian cancer
    Schofield, Christelle
    Lopez, Pedro
    Cohen, Paul A.
    Taaffe, Dennis R.
    Newton, Robert Usher
    Galvao, Daniel A.
    Jeffery, Emily
    Meniawy, Tarek M.
    Peddle-McIntyre, Carolyn J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (10) : 1587 - 1594
  • [37] Disparities in treatment modalities and survival among older patients with high-grade serous ovarian cancer
    Cai, Yan
    Shu, Tong
    Zheng, Hong
    BMC WOMENS HEALTH, 2024, 24 (01)
  • [38] BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
    Ruscito, I.
    Dimitrova, D.
    Vasconcelos, I.
    Gellhaus, K.
    Schwachula, T.
    Bellati, F.
    Zeillinger, R.
    Benedetti-Panici, P.
    Vergote, I.
    Mahner, S.
    Cacsire-Tong, D.
    Concin, N.
    Darb-Esfahani, S.
    Lambrechts, S.
    Sehouli, J.
    Olek, S.
    Braicu, E. I.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (12) : 2090 - 2098
  • [39] Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer
    Zhang, Guodong
    Xu, Qing
    Zhang, Xiangyun
    Yang, Moran
    Wang, Yiying
    He, Mengdi
    Lu, Jiaqi
    Liu, Haiou
    CANCER MEDICINE, 2021, 10 (12): : 3905 - 3918
  • [40] A Computed Tomography-Based Radiomic Prognostic Marker of Advanced High-Grade Serous Ovarian Cancer Recurrence: A Multicenter Study
    Wei, Wei
    Liu, Zhenyu
    Rong, Yu
    Zhou, Bin
    Bei, Yan
    Wei, Wei
    Wang, Shuo
    Wang, Meiyun
    Guo, Yingkun
    Tian, Jie
    FRONTIERS IN ONCOLOGY, 2019, 9